Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Bitsch

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
CNS Drugs|May 25, 2002
Differentiation of multiple sclerosis subtypes: implications for treatmentAndreas Bitsch, Wolfgang Brück
Deutsches Arzteblatt International|October 17, 2019
Anatomy Not Precisely DescribedAndreas Winkelmann, Andreas Bitsch
Brain : a Journal of Neurology|September 24, 2002
Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over timeTanja Kuhlmann, Gueanelle Lingfeld, Andreas Bitsch, et al.
Glia|September 19, 2002
The relative number of macrophages/microglia expressing macrophage colony-stimulating factor and its receptor decreases in multiple sclerosis lesionsKatrin Werner, Andreas Bitsch, Stephanie Bunkowski, et al.
Acta Neurologica Belgica|April 4, 2014
NMDA-receptor antibody and anti-Hu antibody positive paraneoplastic syndrome associated with a primary mediastinal seminomaInga Pohley, Klaus Roesler, Matthias Wittstock, et al.
Journal of Neurology|January 13, 2005
Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1bAndreas Bitsch, Alexander Dressel, Kathrin Meier, et al.
Plos One|September 10, 2013
Fabry disease - underestimated in the differential diagnosis of multiple sclerosis?Tobias Böttcher, Arndt Rolfs, Christian Tanislav, et al.
Neuroscience Letters|June 12, 2002
Interferon-beta-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patientsDirk Bahner, Christine Klucke, Bernd Kitze, et al.
Journal of Neurology|October 31, 2003
Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosisMaryna Yushchenko, Michael Mäder, Ercan Elitok, et al.
European Neurology|January 23, 2002
Serum tau protein level as a marker of axonal damage in acute ischemic strokeAndreas Bitsch, Claudia Horn, Yvonne Kemmling, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
CNS Drugs|May 25, 2002
Differentiation of multiple sclerosis subtypes: implications for treatmentAndreas Bitsch, Wolfgang Brück
Deutsches Arzteblatt International|October 17, 2019
Anatomy Not Precisely DescribedAndreas Winkelmann, Andreas Bitsch
Brain : a Journal of Neurology|September 24, 2002
Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over timeTanja Kuhlmann, Gueanelle Lingfeld, Andreas Bitsch, et al.
Glia|September 19, 2002
The relative number of macrophages/microglia expressing macrophage colony-stimulating factor and its receptor decreases in multiple sclerosis lesionsKatrin Werner, Andreas Bitsch, Stephanie Bunkowski, et al.
Acta Neurologica Belgica|April 4, 2014
NMDA-receptor antibody and anti-Hu antibody positive paraneoplastic syndrome associated with a primary mediastinal seminomaInga Pohley, Klaus Roesler, Matthias Wittstock, et al.
Journal of Neurology|January 13, 2005
Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1bAndreas Bitsch, Alexander Dressel, Kathrin Meier, et al.
Plos One|September 10, 2013
Fabry disease - underestimated in the differential diagnosis of multiple sclerosis?Tobias Böttcher, Arndt Rolfs, Christian Tanislav, et al.
Neuroscience Letters|June 12, 2002
Interferon-beta-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patientsDirk Bahner, Christine Klucke, Bernd Kitze, et al.
Journal of Neurology|October 31, 2003
Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosisMaryna Yushchenko, Michael Mäder, Ercan Elitok, et al.
European Neurology|January 23, 2002
Serum tau protein level as a marker of axonal damage in acute ischemic strokeAndreas Bitsch, Claudia Horn, Yvonne Kemmling, et al.
Pageof 2